Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
Date:10/30/2008

Increases 2008 Adjusted EPS Guidance to $0.64 - $0.67 from Prior Range of

$0.47 - $0.53 Reaffirms Adjusted EPS Guidance of $0.90 - $1.10 for 2009 and $1.50 - $1.70

for 2010

PITTSBURGH, Oct. 30 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced its financial results for the three and nine months ended Sept. 30, 2008.

Financial Highlights

-- Adjusted diluted EPS of $0.23 and $0.52 for the three and nine months ended Sept. 30, 2008, respectively, which excludes the impact of certain purchase accounting items as well as other non-recurring items as discussed in detail below;

-- Total revenues of $1.66 billion for the three months ended Sept. 30, 2008, an increase of $1.18 billion over the same prior year period;

-- Total revenues for the current quarter includes the recognition of approximately $455.0 million of previously deferred revenue related to the sale of the company's rights to Bystolic(TM);

-- On a GAAP basis the company reported earnings per diluted share of $0.45 for the three months ended Sept. 30, 2008, and a loss per diluted share of $0.92 for the nine months ended Sept. 30, 2008.

-- Included in the GAAP results for the year-to-date period is a non-cash goodwill impairment charge of $385.0 million recorded in the first quarter related to the Specialty Segment.

"As we have reached the one year anniversary of our acquisition of Merck KGaA's generics business, I am extremely pleased with the progress that we continue to make in combining the strengths of three high quality businesses, Mylan, Matrix and the former Merck Generics, into one well-positioned and powerful global platform. Led by a robust
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Progyny, Inc., the new ... announced that it has secured additional capital from investors ... SR One and Merck Serono Ventures. The funding will ... the best fertility outcomes by aligning science, technology, clinics ... marketplace for families seeking fertility solutions and we are ...
(Date:4/21/2015)... YourEncore, an Indianapolis, Indiana-based company that ... and food sciences industries solve complex development, regulatory ... Research Excellence and Safety (ACRES), a Massachusetts-based non-profit ... have partnered to speed innovation in the medical ... to ACRES experts with proven experience, tools, and ...
(Date:4/20/2015)... Texas , April 20, 2015 ... surgeons for healing bone injuries. The orthobiologics market is ... opportunities for its stakeholders. The global orthobiologics market report ... forecast of revenue. The global orthobiologics market was valued ... reach $7,900.2 million by 2019, at a CAGR of ...
(Date:4/20/2015)... 2015  "Everybody is affected by cancer sooner or ... frankly brutal. We,ve got to get away from that."  ... witnessed a loved one or friend battling for their ... chemotherapy and other treatments cause the human body. It,s ... up and succumb to the disease. Dr. Dionne has ...
Breaking Biology Technology:Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2
... Soyfoods Even HealthierST. LOUIS, March 31 Recent research ... to be beneficial to the diet. And, the majority ... products such as soyfoods even healthier. These findings come ... Survey - sponsored by the United Soybean Board ...
... 30 BioSpecifics Technologies Corp. (Nasdaq: BSTC ... products, today announced its financial results for the fourth ... are very happy to report that our partner Auxilium ... enrollment in a Phase IIb trial in Peyronie,s disease ...
... 30 Mylan Inc. (Nasdaq: MYL ) ... in which it holds a 71.2% controlling interest, has ... and Drug Administration (FDA) under the President,s Emergency Plan ... Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, ...
Cached Biology Technology:Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 2Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 4BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 5BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 7Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R) 2
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... with a number of pathological conditions, including cancer. Publishing in ... in drinking water given at the maximum levels permitted ... in mice. On the other hand, reducing copper levels reduced ... essential factor for the growth of tumors in humans as ...
... Hall Institute have been awarded more than $2.2 million from ... disorders and inflammatory diseases. Three institute researchers - ... - were announced last week as recipients of ARC Future ... body controls errant immune cells that cause type 1 diabetes ...
... , Nov. 14, 2013  Based on its recent research ... presents Cognitec Systems GmbH with the 2013 European ... Cognitec,s blinkers-on focus on face biometrics earned the ... to develop its flagship face recognition technology, FaceVACS-VideoScan. ...
Cached Biology News:Copper intake makes tumors breathe 2ARC Future Fellows awarded $2.2M for immune and inflammation studies 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 3Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 4Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 5
... I (RNase-free) (E.C. 3.1.21.1) is a nonspecific ... chromatin. It functions by hydrolyzing phosphodiester linkages, ... and a 3'-hydroxyl group. Ambion's RNase-free DNase ... and is recommended to degrade DNA in ...
hnRNP U (H-94)...
... contains a unique β-agarose digesting enzyme developed ... intact DNA and RNA from low melting ... TAE, TBE, MOPS, or phosphate buffers. The ... TAE, TBE, MOPS, and phosphate electrophoresis buffers ...
... is causing shortages in your laboratory or ... cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us ... up,and market it internationally. We work under ...
Biology Products: